ArticleCell division2026
p53 overexpression counteracts the pro-survival effect of Bcl-2 by restoring MAMs function in cutaneous squamous cell carcinoma.
Article in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCutaneous squamous cell carcinoma (cSCC) is a prevalent type of skin cancer, and its development is strongly associated with impaired regulation of apoptosis. The anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) and the tumor suppressor p53 play pivotal roles in controlling apoptotic signaling. Although Bcl-2 expression in cSCC has been reported to be heterogeneous, its role in mitochondria-associated membranes (MAMs)-mediated apoptosis remains unclear. This study aims to clarify how Bcl-2 and p53 regulate cSCC cell apoptosis by modulating the structure and function of MAMs.
methodsWe constructed stable Bcl-2 overexpression (oe-Bcl-2) and Bcl-2/p53 co-overexpression (oe-Bcl-2 + oe-p53) A431 cell lines using lentiviral transduction. Transcriptome sequencing (RNA-seq) was performed, followed by pathway enrichment and protein-protein interaction (PPI) network analyses to screen for critical signaling routes. Cell apoptosis, growth, migratory capacity, and invasive potential were evaluated using flow cytometry, CCK-8, EdU incorporation, colony formation, and Transwell-based assays. Key MAMs functions, including Ca
resultsRNA-seq analysis revealed that Bcl-2 regulates multiple apoptosis- and calcium signaling-related pathways, significantly affecting key MAM-associated proteins, including VDAC2, IP3R, SERCA2, as well as the p53 signaling pathway. Bcl-2 overexpression markedly enhanced proliferation and migration of A431 cells while reducing apoptosis. It also modulated mitochondrial membrane potential, ATP production, and ROS generation, suggesting that Bcl-2 exerts anti-apoptotic effects through MAMs. In contrast, Bcl-2 knockdown significantly suppressed proliferation and invasion while inducing apoptosis in A431 cells, further supporting its oncogenic role. Notably, p53 overexpression reversed these effects and significantly inhibited tumor growth in vivo.
conclusionOur findings demonstrate that Bcl-2 promotes cSCC progression by modulating MAMs structure and function to inhibit p53-mediated mitochondrial apoptosis. The study identifies the novel Bcl-2-MAMs-p53 signaling axis that plays a pivotal role in determining cSCC cell fate, highlighting a promising target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.